This clinical trial is focused on studying treatments for HER2-positive breast cancer, which is a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein promotes the growth of cancer cells. The study involves several medications, including Atezolizumab, Pertuzumab, and Trastuzumab, which are used in combination with chemotherapy. These medications are designed to target and block the HER2 protein, helping to slow or stop the growth of cancer cells.
The purpose of the study is to compare the effectiveness of different treatment combinations in improving the 5-year event-free survival of patients. Event-free survival refers to the length of time after treatment during which a patient remains free from certain complications or events that the study is measuring. Participants will receive treatment over a period of time, and their health will be monitored to assess the outcomes. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatments.
Throughout the study, participants will undergo regular health assessments to monitor their response to the treatment. The study aims to provide valuable information on the best treatment strategies for patients with HER2-positive breast cancer, potentially leading to improved outcomes and survival rates. The trial is expected to conclude by the end of 2026, with results helping to guide future treatment approaches for this type of cancer.



Austria
Belgium
Germany
Italy
Romania
Spain